Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is the
developer of the drug-delivery platform DehydraTECH(TM). The company’s
innovative technology promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. An article
discussing the company reads, “One of the delivery challenges is the amount of
CBD waste created, because the human body can only absorb a small amount of the
molecules. DehydraTECH is disrupting this cycle by protecting the product
during stomach transit, amplifying intestinal absorption by five to ten times
over traditional methods and enabling the drug to bypass first-pass liver
metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC
effects in humans when using the edible tech. . . . Products that use the
DehydraTECH drug-delivery platform have been shown to deliver CBD faster than
those that use medium-chain triglyceride oils. A recent study reported a 319%
higher CBD blood concentration at 60 minutes when using the DehydraTECH
formulation as opposed to coconut oil (http://ibn.fm/tKbuo). Fatty acids used with DehydraTECH
have the added benefit of masking the bitter taste of CBD, allowing a better
overall experience for the consumer without the need for added sugars or
chemicals.”
To view the full article, visit http://ibn.fm/0yWPp
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive,
patented-delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment